Assembly biosciences provides update on its core inhibitor pipeline, reports fourth quarter and year end 2022 financial results and recent highlights

South san francisco, calif., march 22, 2023 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an update on its investigational next-generation hepatitis b virus (hbv) core inhibitors, abi-h3733 (3733) and abi-4334 (4334), and reported financial results and recent highlights for the fourth quarter and year ended december 31, 2022.
ASMB Ratings Summary
ASMB Quant Ranking